Automated stem cell-derived organoid platforms for disease modeling.

Area of Science:

• Biotechnology
• Stem Cell Biology
• Disease Modeling

Background:

• Complex diseases result from intricate genetic, environmental, and lifestyle interactions, posing significant modeling challenges.
• Traditional animal and 2D cell models lack scalability, reproducibility, and human relevance for studying complex diseases.
• Current human organoid models, while promising, face limitations in protocol duration, variability, and labor intensity, hindering high-throughput applications.

Purpose of the Study:

• To explore the potential of combining human-induced pluripotent stem cells (iPSCs)-derived organoids with automation for advanced disease modeling.
• To address the limitations of current organoid technologies, including scalability, reproducibility, and labor intensity.
• To highlight the transformative impact of automated organoid systems on drug discovery and development.

Main Methods:

• Utilizing human-induced pluripotent stem cells (iPSCs) for differentiation into 3D organoids.
• Implementing suspension bioreactors and multilineage differentiation techniques to enhance organoid yield and function.
• Integrating automated high-throughput liquid handling systems for large-scale and reproducible organoid production.

Main Results:

• Automation enables scalable and reproducible production of iPSC-derived organoids.
• Advancements in bioreactor and differentiation techniques improve organoid yield and functionality.
• Overcoming challenges in tissue maturity, vascularization, and consistency is crucial for robust organoid models.

Conclusions:

• The integration of automation with iPSC-derived organoids represents a significant advancement in disease modeling.
• Automated organoid platforms are poised to revolutionize drug development by enabling high-throughput, human-relevant screening.
• This approach offers a pathway to more accurate and efficient preclinical research for complex human diseases.